{
  "docId": "019de516-48a5-7631-970d-a6192a59c040",
  "docSlug": "5b4cac48a3342d745accb48141e027b4",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 39 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 39,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-48a5-7631-970d-a6192a59c040/7",
  "deckHref": "/decks/019de516-48a5-7631-970d-a6192a59c040",
  "deckJsonHref": "/decks/019de516-48a5-7631-970d-a6192a59c040.json",
  "deckAnchorHref": "/decks/019de516-48a5-7631-970d-a6192a59c040#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.31,
        "w": 0.239,
        "x": 0.099,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Pharmaceuticals 19%, Surgical 19%, Vision Care 62%",
      "attrs": {},
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a6fbca9-d1eb-40ff-9150-34b5a8041846",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.099,
        "w": 0.202,
        "x": 0.125,
        "y": 0.22
      },
      "kind": "list",
      "text": "2Q23 vs. 2Q22\n10% Reported Revenue Growth\n12% CC³ Revenue Growth¹",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b9f02bc-42de-4c5b-a6b4-919a0ba12f42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.51,
        "w": 0.202,
        "x": 0.36,
        "y": 0.34
      },
      "kind": "list",
      "text": "Vision Care²\n2Q23 REPORTED REVENUE\n$646M\n2Q23 CONSTANT CURRENCY\nREVENUE GROWTH¹\n+12%\nGrowth momentum in Lumify,\nDaily SiHy, Eye Vitamins, Artelac\nSystem upgrade at U.S. distribution\nfacility impacted lens business",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f70d37c-18aa-497e-9c38-12577377582b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.51,
        "w": 0.202,
        "x": 0.58,
        "y": 0.34
      },
      "kind": "list",
      "text": "Surgical\n2Q23 REPORTED REVENUE\n$195M\n2Q23 CONSTANT CURRENCY\nREVENUE GROWTH¹\n+7%\nContinued strength in demand,\ngrowth in Premium IOL portfolio\nFocused on providing\nconsistent supply of products",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ee7fcbd-8953-41de-a674-cd573b22c366",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.51,
        "w": 0.17,
        "x": 0.801,
        "y": 0.34
      },
      "kind": "list",
      "text": "Pharmaceuticals 2,4\n2Q23 REPORTED REVENUE\n$194M\n2Q23 CONSTANT CURRENCY\nREVENUE GROWTH¹\n+16%\nGrowth across all major\nmarkets including China\nStrong execution in\nU.S. Gx portfolio",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4681740-aad5-4550-abf6-a141ba890b3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.147,
        "y": 0.57
      },
      "kind": "metric",
      "text": "$1,035M",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86ffbccd-4d69-49c9-94b1-4f5b718304f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.08,
        "x": 0.046,
        "y": 0.825
      },
      "kind": "metric",
      "text": "$179M",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6e26613-4bec-430a-935a-24d7f1aa9f44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.17,
        "x": 0.133,
        "y": 0.825
      },
      "kind": "paragraph",
      "text": "2Q23 Adj. EBITDA¹\n~$25M FX headwinds",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83d7f37d-3fed-4daf-b99e-cff85fd2129e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.74,
        "x": 0.183,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.\n2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported\nresults of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The\nnet impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.\n3. Constant currency.\n4. Effective as of the second quarter of 2023, the company changed the name of the segment from \"Ophthalmic Pharmaceuticals\" to \"Pharmaceuticals\". Aside from the change in name, there were no other changes to the segment itself as a result.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efc101f2-cf8c-41e1-a067-9a4942db57aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.908,
        "x": 0.046,
        "y": 0.08
      },
      "kind": "title",
      "text": "Double Digit Total Revenue Growth with Strong Performance Across All Segments",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d33647f4-af1a-40b1-b66d-babef6834ae6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "e8b042d1-8e37-4976-9e22-40d7111a9232",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The company presents its opportunity to leverage infrastructure to drive profitable growth.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 8,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "0e393959-56ca-43c9-9bc8-c762711348e8",
      "evidence": "The company presents the opportunity to leverage infrastructure to drive profitable growth.",
      "position": 0,
      "objective": "What are the consequences of not leveraging infrastructure to drive growth?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}